The FIRE AND ICE trial (NCT01490814) was a multicentre, randomized, blinded-outcomes, parallel-group evaluation of cryoballoon and RFC catheter ablation in patients being treated for drug-refractory and symptomatic paroxysmal AF.
1 (link),2 (link) A study design manuscript and the primary endpoints have been separately published.
1 (link),2 (link) In brief, each treatment centre approved the study design with their local ethics review committee(s), and patient informed consent was obtained prior to enrolment. Patients were randomized to either cryoballoon ablation using the Arctic Front™ family of catheters (Medtronic) or RFC catheter ablation using the ThermoCool
® series of catheters (Biosense Webster).
During the index procedure, the (1:1) randomly selected ablation modality was used in the left atrium to electrically isolate the pulmonary veins (PVs).
3–5 (link) In the cryoballoon procedures, pulmonary vein isolation (PVI) was achieved using fluoroscopic guidance to position the cryoballoon catheter. Once PV-to-balloon occlusion was confirmed by retrograde radiopaque contrast agent retention, circumferential ablation was performed by freezing with a ‘single-shot’ delivery of coolant to the balloon. In the RFC procedure, PVI was achieved using a focal ‘point-by-point’ catheter approach, which delivers heat energy to the cardiac tissue. RFC lesion sets encircle the PV antra using electroanatomical mapping for guidance. In both cohorts, a PVI-only strategy was used to ablate AF, and acute index procedure success was documented in both arms with diagnostic testing. All investigators demonstrated the success of PVI by the abolition of conduction of atrial impulses into the PVs. After the index procedure, subjects were followed in this study for up to 33 months.
1 (link),2 (link) In both groups, subjects were followed-up for a mean time of 1.54 ± 0.8 years.
1 (link)In the publication of the primary endpoints, the data were presented as time-to-first event reported per subject, and a 90-day blanking period was predefined.
1 (link) Recurrences of atrial arrhythmias and repeat ablations within the 90-day blanking period did not contribute towards the primary endpoint.
1 (link) However, robust clinical data were collected (on reinterventions and rehospitalizations) in this trial both within the 90-day blanking period and after the primary endpoint event to allow for the analyses of the current presented endpoints. The data presented in this current analysis are the total clinical events that were documented in this trial from the index procedure through the study exit for each subject to provide a comprehensive summary of the disease burden to the patients and to the healthcare systems.
Kuck K.H., Fürnkranz A., Chun K.R., Metzner A., Ouyang F., Schlüter M., Elvan A., Lim H.W., Kueffer F.J., Arentz T., Albenque J.P., Tondo C., Kühne M., Sticherling C, & Brugada J. (2016). Cryoballoon or radiofrequency ablation for symptomatic paroxysmal atrial fibrillation: reintervention, rehospitalization, and quality-of-life outcomes in the FIRE AND ICE trial. European Heart Journal, 37(38), 2858-2865.